Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) announced that the U.S. Food and Drug Administration (FDA) enjoy designated the Companies’ histone deacetylase (HDAC) inhibitor, MGCD0103, using an Orphan Drug in travel to of the analysis of acute myelogenous leukemia (AML) in the United States. Criteria for designation call upon for that […]
NAVIGATION
|
28
Aug |
Pharmion And MethylGene Announce U.S. Orphan Drug Designation Granted For MGCD0103 For The Treatment Of Acute Myelogenous LeukemiaCategory: Uncategorized | Leave a Comment |